SubHero Banner

Jardiance® (empagliflozin), Synjardy® (empagliflozin/metformin) – Expanded indication

June 20, 2023 - The FDA announced the approval of Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and Synjardy (empagliflozin/metformin), as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM).

Download PDF